📊 FEMY Key Takeaways
Is Femasys Inc. (FEMY) a Good Investment?
FEMY is a pre-commercial/early-stage medical device company with severe operational burn. Operating cash outflow of $4.1M annually against $424.9K revenue represents an unsustainable 9.6x burn-to-revenue ratio, providing approximately 1.3 years of cash runway at current burn rates. While 40.8% YoY revenue growth and zero debt are positive signals, the company lacks a clear path to profitability without dramatic revenue acceleration or material cost reduction.
Femasys shows early revenue growth, but the absolute scale of the business remains far too small relative to its operating cost structure. Losses are extreme versus revenue, cash burn is heavy, and liquidity is only marginal, which makes the current growth profile low quality and financially fragile. The debt-free balance sheet helps, but fundamentals still point to a business that likely needs substantial operating improvement or external capital to sustain itself.
Femasys Inc. Key Strengths (FEMY)
- Strong revenue growth of 40.8% YoY demonstrates market adoption potential
- Healthy balance sheet with no long-term debt and $5.4M cash reserves
- Excellent liquidity position with 3.91x current ratio and 1.98x quick ratio
- Revenue grew 52.0% year over year, indicating some commercial traction
- The company has no meaningful long-term debt, reducing balance sheet leverage risk
- Cash roughly matches stockholders' equity, providing some near-term operating flexibility
FEMY Stock Risks: Femasys Inc. Investment Risks
- Massive operating cash burn of -$4.1M annually against only -$424.9K revenue is fundamentally unsustainable
- Limited cash runway of approximately 1.3 years at current burn rate without additional financing
- Company remains in pre-profitable stage with operating margin of -994% and no clear inflection point
- Data quality concerns including impossible >100% gross margins and net income positive despite operating losses suggest potential accounting anomalies or one-time gains masking operational weakness
- Operating and net margins are deeply negative, showing the business model is not close to breakeven
- Free cash flow and operating cash flow are severely negative, implying continued cash consumption
- Liquidity is weak with a 1.16x current ratio and 0.61x quick ratio, raising funding risk if burn continues
Key Metrics to Watch
- Quarterly operating cash flow trend and year-over-year change in cash burn rate
- Revenue growth acceleration to demonstrate pathway to positive unit economics
- Operating expense reduction or gross margin improvement to show progress toward profitability
- Quarterly revenue growth versus operating expense growth
- Cash runway and improvement in operating cash flow/free cash flow
Femasys Inc. (FEMY) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.91x current ratio provides a solid financial cushion.
FEMY Profit Margin, ROE & Profitability Analysis
FEMY vs Healthcare Sector: How Femasys Inc. Compares
How Femasys Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Femasys Inc. Stock Overvalued? FEMY Valuation Analysis 2026
Based on fundamental analysis, Femasys Inc. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Femasys Inc. Balance Sheet: FEMY Debt, Cash & Liquidity
FEMY Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Femasys Inc.'s revenue has grown significantly by 94% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.85 indicates the company is currently unprofitable.
FEMY Revenue Growth, EPS Growth & YoY Performance
FEMY Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $341.3K | $846.1K | $0.00 |
| Q3 2025 | $554.9K | -$4.2M | $-0.10 |
| Q2 2025 | $221.5K | -$4.6M | $-0.16 |
| Q1 2025 | $271.1K | -$3.6M | $-0.17 |
| Q3 2024 | $244.4K | -$4.0M | $-0.24 |
| Q2 2024 | $221.5K | -$2.9M | $-0.21 |
| Q1 2024 | $271.1K | -$2.9M | $-0.17 |
| Q3 2023 | $244.4K | -$3.0M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Femasys Inc. Dividends, Buybacks & Capital Allocation
FEMY SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Femasys Inc. (CIK: 0001339005)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FEMY
What is the AI rating for FEMY?
Femasys Inc. (FEMY) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FEMY's key strengths?
Claude: Strong revenue growth of 40.8% YoY demonstrates market adoption potential. Healthy balance sheet with no long-term debt and $5.4M cash reserves. ChatGPT: Revenue grew 52.0% year over year, indicating some commercial traction. The company has no meaningful long-term debt, reducing balance sheet leverage risk.
What are the risks of investing in FEMY?
Claude: Massive operating cash burn of -$4.1M annually against only -$424.9K revenue is fundamentally unsustainable. Limited cash runway of approximately 1.3 years at current burn rate without additional financing. ChatGPT: Operating and net margins are deeply negative, showing the business model is not close to breakeven. Free cash flow and operating cash flow are severely negative, implying continued cash consumption.
What is FEMY's revenue and growth?
Femasys Inc. reported revenue of $424.9K.
Does FEMY pay dividends?
Femasys Inc. does not currently pay dividends.
Where can I find FEMY SEC filings?
Official SEC filings for Femasys Inc. (CIK: 0001339005) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FEMY's EPS?
Femasys Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is FEMY's fundamental grade?
Based on our AI fundamental analysis in June 2026, Femasys Inc. has a C grade with 80% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is FEMY stock overvalued or undervalued?
Valuation metrics for FEMY: ROE of 11.6% (sector avg: 15%), net margin of 199.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is FEMY's AI grade for 2026?
Our dual AI analysis gives Femasys Inc. a combined C grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is FEMY's free cash flow?
Femasys Inc.'s operating cash flow is $-4.1M, with capital expenditures of $79.1K. FCF margin is -993.8%.
How does FEMY compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 199.1% (avg: 12%), ROE 11.6% (avg: 15%), current ratio 3.91 (avg: 2).